EP1146883A4 - Modulation of immune response by ribavirin - Google Patents

Modulation of immune response by ribavirin

Info

Publication number
EP1146883A4
EP1146883A4 EP99968159A EP99968159A EP1146883A4 EP 1146883 A4 EP1146883 A4 EP 1146883A4 EP 99968159 A EP99968159 A EP 99968159A EP 99968159 A EP99968159 A EP 99968159A EP 1146883 A4 EP1146883 A4 EP 1146883A4
Authority
EP
European Patent Office
Prior art keywords
ribavirin
modulation
immune response
immune
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99968159A
Other languages
German (de)
French (fr)
Other versions
EP1146883A1 (en
Inventor
Robert Tam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Pharmaceuticals International Inc USA
Original Assignee
ICN Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICN Pharmaceuticals Inc filed Critical ICN Pharmaceuticals Inc
Priority to DE29924200U priority Critical patent/DE29924200U1/en
Publication of EP1146883A1 publication Critical patent/EP1146883A1/en
Publication of EP1146883A4 publication Critical patent/EP1146883A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EP99968159A 1999-01-29 1999-12-20 Modulation of immune response by ribavirin Withdrawn EP1146883A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE29924200U DE29924200U1 (en) 1999-01-29 1999-12-20 Modulation of an immune response by ribavirin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24136799A 1999-01-29 1999-01-29
US241367 1999-01-29
PCT/US1999/030490 WO2000044388A1 (en) 1999-01-29 1999-12-20 Modulation of immune response by ribavirin

Publications (2)

Publication Number Publication Date
EP1146883A1 EP1146883A1 (en) 2001-10-24
EP1146883A4 true EP1146883A4 (en) 2004-11-24

Family

ID=22910442

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99968159A Withdrawn EP1146883A4 (en) 1999-01-29 1999-12-20 Modulation of immune response by ribavirin

Country Status (20)

Country Link
EP (1) EP1146883A4 (en)
JP (1) JP2002535371A (en)
KR (1) KR20020023939A (en)
CN (1) CN1334736A (en)
AU (1) AU2483300A (en)
BR (1) BR9917090A (en)
CA (1) CA2357735A1 (en)
CZ (1) CZ20012519A3 (en)
HK (1) HK1040937A1 (en)
HR (1) HRP20010496A2 (en)
HU (1) HUP0200027A2 (en)
IL (1) IL144130A0 (en)
MX (1) MXPA01007211A (en)
NO (1) NO20013529L (en)
PL (1) PL364699A1 (en)
RU (1) RU2211698C2 (en)
SI (1) SI20802A (en)
SK (1) SK10092001A3 (en)
WO (1) WO2000044388A1 (en)
ZA (1) ZA200105595B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
AU2001290178A1 (en) 2000-08-17 2002-02-25 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
RU2286172C2 (en) 2000-08-17 2006-10-27 Трипеп Аб Ribavirin-containing vaccines and methods for their application
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN101410122A (en) * 2006-03-14 2009-04-15 厚生药业股份有限公司 Method and composition for treating anaphylactic disease
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
EP0038629A1 (en) * 1980-04-17 1981-10-28 Beecham Group Plc Virazole derivatives, process for their preparation and use as antiviral agents
WO1987005807A1 (en) * 1986-03-27 1987-10-08 Harry Edward Gruber A method of increasing adenosine excretion
EP0383361A2 (en) * 1984-10-29 1990-08-22 Viratek, Inc. 1-Beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide for use in medical treatment of humans
US5030623A (en) * 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
WO1997026883A1 (en) * 1996-01-23 1997-07-31 Icn Pharmaceuticals, Inc. Modulation of th1/th2 cytokine expression by ribavirin® and ribavirin® analogs in activated t-lymphocytes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
RU2188828C2 (en) * 1996-10-16 2002-09-10 Ай-Си-Эн Фармасьютикалз, Инк. Monocyclic l-nucleosides, their analogues and using

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
EP0038629A1 (en) * 1980-04-17 1981-10-28 Beecham Group Plc Virazole derivatives, process for their preparation and use as antiviral agents
EP0383361A2 (en) * 1984-10-29 1990-08-22 Viratek, Inc. 1-Beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide for use in medical treatment of humans
EP0643970A2 (en) * 1984-10-29 1995-03-22 Viratek, Inc. 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide for use in medical treatment of humans
WO1987005807A1 (en) * 1986-03-27 1987-10-08 Harry Edward Gruber A method of increasing adenosine excretion
US5030623A (en) * 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
WO1997026883A1 (en) * 1996-01-23 1997-07-31 Icn Pharmaceuticals, Inc. Modulation of th1/th2 cytokine expression by ribavirin® and ribavirin® analogs in activated t-lymphocytes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0044388A1 *

Also Published As

Publication number Publication date
NO20013529L (en) 2001-09-12
HUP0200027A2 (en) 2002-04-29
WO2000044388A1 (en) 2000-08-03
IL144130A0 (en) 2002-05-23
MXPA01007211A (en) 2002-05-06
ZA200105595B (en) 2002-10-07
CA2357735A1 (en) 2000-08-03
NO20013529D0 (en) 2001-07-17
BR9917090A (en) 2001-10-16
CN1334736A (en) 2002-02-06
SK10092001A3 (en) 2002-02-05
EP1146883A1 (en) 2001-10-24
AU2483300A (en) 2000-08-18
KR20020023939A (en) 2002-03-29
HK1040937A1 (en) 2002-06-28
SI20802A (en) 2002-08-31
RU2211698C2 (en) 2003-09-10
PL364699A1 (en) 2004-12-13
CZ20012519A3 (en) 2002-05-15
HRP20010496A2 (en) 2003-08-31
JP2002535371A (en) 2002-10-22

Similar Documents

Publication Publication Date Title
GB2352493B (en) Single piece piston
EP1230462A4 (en) Hoardings
GB2357023B (en) Cooker
IL145891A0 (en) Methods and compositions for modulating an immune response
GB2356024B (en) Electromagnetic diaphagm pump
ZA200109206B (en) Preparation of substituted piperidin-4-ones.
IL144130A0 (en) Modulation of immune response by ribavirin
GB9929891D0 (en) Exciplexes
EP1300681A4 (en) Means of assaying immune function
GB9807062D0 (en) Immune response
GB9822619D0 (en) Immune response stimulation
GB2346223B (en) Governor
AU6074000A (en) Human immune response molecules
CA85805S (en) Walker
CA85813S (en) Walker
HU9902379D0 (en) Firering and dust-separator apparatous to utilize plant-wastes by air-protecting way
GB9914659D0 (en) Easy walker
GB9924775D0 (en) Immune response stimulation
GB9915260D0 (en) Modification to the works of an airgun
GB9905127D0 (en) Child tracker
GB9924096D0 (en) Supplement
HK1020479A2 (en) Liquid-filled ornament
GB9919460D0 (en) Stalker
AU140925S (en) Puppet
AU140878S (en) Puppet

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ICN PHARMACEUTICALS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20041013

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040701

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1040937

Country of ref document: HK